# Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.

> **NCT02017860** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 4 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT02017860
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-16
- **Primary completion:** 2019-04-25
- **Final completion:** 2019-04-25
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2020-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02017860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02017860, "Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02017860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*